The Alpha-1 Foundation is dedicated to providing the leadership and resources that will result in increased research, improved health, worldwide detection and a cure for Alpha-1 Antitrypsin Deficiency. Alpha-1 Antitrypsin (AAT) Deficiency is a hereditary condition which may result in serious lung disease in adults and/or liver disease in infants, children and adults. The Foundation has realized continuous growth since its inception in 1995 and has developed a solid infrastructure to promote research and the development of new therapies for improving the quality of life for those diagnosed with AAT Deficiency. The Foundation has invested more than $35 million to support Alpha-1 Antitrypsin research and programs in 60 institutions in North America and Europe.
